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Higher organisms contain two types of cells: postmitotic 
cells, which never divide, and mitotic (or mitotically 
competent) cells, which can divide. Postmitotic cells 
include mature nerve, muscle, and fat cells, some of 
which persist for life. Mitotic cells include epithelial 
and stromal cells of organs such as the skin. Because 
postmitotic and mitotic cells differ in their proliferative 
capacity, they may age by different mechanisms. Normal 
somatic mitotically competent cells do not divide 
indefinitely. The process that limits the cell division 
number is termed cellular or replicative senescence. 
Replicative senescence is thought to be a powerful, 
albeit imperfect, tumor suppressive mechanism. It is also 
thought to contribute to organismic aging. Senescent 
cells undergo three phenotypic changes: they irreversibly 
arrest growth, they acquire resistance to apoptotic death, 
and they acquire altered differentiated functions. The 
A ging is a complex process, and thus several hypotheses have been proposed to explain it (see Finch, 1990, for review). These hypotheses £ill into two main categories. The first invokes extrinsic or intrinsic damage to intracellular or extracellular molecules. This damage is 
thought to compromise tissues because dysfunctional molecules or cells 
accumulate, or damaged cells die and are not replaced. The second 
category invokes programmed or epigenetic changes in gene expression. 
These changes are thought to compromise tissues because terminally 
nondividing cells with altered phenotypes accumulate. A major gene 
expression hypothesis proposes that cell division is the driving force 
behind the eventual loss of division capacity and change in phenotype. 
This loss of proliferative capacity has been termed replicative or cellular 
senescence. This article reviews what is known about cell senescence 
and its role in the aging of organs such as the skin. 
Higher organisms contain both postrnitotic (permanendy nondivid­
ing) and mitotic (proliferation-competent) cells, and thus aging may 
not entail only a single mechanism. Aging may be due to programmed 
changes in gene expression in mitotic cells and damage in postrnitotic 
cells. Similarly, aging may be due to an accumulation of cells in altered 
or late stages of differentiation in mitotic tissues, and cell loss postmitotic 
tissues. Moreover, extracellular material (e.g., collagens, elastin, etc.) 
undergo age-dependent changes. Clearly, postrnitotic cells, which do 
not replicate, do not undergo replicative senescence. Rather, replicative 
senescence alters the phenotype of mitotic cells only. As such, replicative 
senescence is expected to comprise but one component of aging (Fig 1). 
Replicative senescence ensures that most higher eukaryotic cells that 
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growth arrest is very likely critical for the role of rep­
licative senescence in tumor suppression, but may be less 
important for the aging of organs such as the skin. On 
the other hand, the altered differentiation may be critical 
for compromising the function and integrity of organs 
like the skin during aging. Senescent keratinocytes and 
fibroblasts appear to accumulate with age in human skin. 
Moreover, senescent cells express genes that have long­
range, pleiotropic effects - degradative enzymes, growth 
factors, and inflammatory cytokines. Thus, relatively few 
senescent cells might compromise skin function and 
integrity. Moreover, by altering the tissue microenviron­
ment, senescent cells may also contribute to the rise 
in cancer that occurs with age. Key words: cell cycle/ 
dilferentiation/ extracellular matrix/microenvironment. Journal 
of Investigative Dermatology Symposium Proceedings 3:1-5, 
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can divide in vivo do not do so indefrnitely, probably, as discussed 
below, in order to curtail tumorigenesis. Thus, normal cells are said to 
have a frnite division potential or replicative life-span. It was not until 
about three decades ago that the fInite replicative life-span of cells was 
fIrst formally described (Hayflick, 1965). Since then, many cell types 
from a variety of animal species have been shown to have a fInite 
replicative life-span. Most studies of replicative senescence have used 
cells grown in culture; however, a limited number of studies using 
cells passaged in intact animals, or cells identifIed in intact tissues, 
strongly suggest that cells undergo replicative senescence in vivo 
(reviewed in Stanulis-Praeger, 1987; Campisi et aI, 1996). 
RESULTS 
Replicative senescence, tumorigenesis, and aging Normal 
somatic cells inevitably undergo replicative senescence, unless they 
harbor mutations or viral oncogenes that allow them to acquire an 
immortal (replicative) life-span (Le., divide indefinitely) (Fig 2). 
Replicative senescence is extremely stringent in human cells, which 
rarely spontaneously give rise to immortal variants. By contrast, cells 
from many rodent species spontaneously immortalize at detectable 
frequencies (Hayflick, 1965; Ponten, 1976; McCormick and Maher, 
1988; Shay and Wright, 1991). 
W hen cells reach the end of their replicative life-span, they arrest 
growth with a G1 DNA content. This growth arrest is essentially 
irreversible, and senescent cells cannot be stimulated to enter the S 
phase of the cell cycle, much less divide, by any combination of 
physiologic mitogens (Hayilick, 1965). The irreversible growth arrest 
of senescent cells, in conjUllction with substantial cell and molecular 
biologic data (reviewed in Campisi et aI, 1996), support the idea that 
replicative senescence is a powerful (but, of course, imperfect) tumor 
suppressive mechanism. Recent evidence suggests that senescent cells 
become resistant to apoptotic death (Wang, 1995). This feature of 
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Figure 1. Fundamental aging processes. Higher organisms are composed 
of two basic cell types - postmitotic and mitotically competent (mitotic) cells -
as well as extracellular materiaL These three entities may age by fundamentally 
different mechanisms. Certainly in the case of cells, mitotic cells undergo 
replicative senescence, whereas postrnitotic cells do not. 
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Figure 2. Proliferative potential of normal and tumor cells. The majority 
of normal somatic cells do not proliferate indefinitely due to the process of 
replicative, or cellular, senescence. Replicative senescence depends on the 
number of cell divisions or cell population doublings, and is particularly stringent 
in cells of human origin. 
replicative senescence may at least partially explain the recent finding 
that senescent cells exist and accumulate in aging human skin (Dimri 
et aI, 1995). Finally, there is substantial evidence that senescent cells 
show some times striking changes in differentiated function (reviewed 
in Campisi et aI, 1996; Campisi, 1997b). The altered function of 
senescent cells, in conjunction with the evidence that they accumulate 
in aged tissues and that the number of divisions at which senescence 
occurs depends inversely on the age of the donor, supports the 
idea that replicative senescence also contributes to organismic aging 
(Campisi, 1996). According to this idea, the accumulation of dysfunc­
tional senescent cells would compromise tissue function and integrity, 
leading to the decline in tissue homeostasis that occurs with age. 
At first glance, the ideas that replicative senescence can contribute 
to both tumor suppression and aging may seem at odds with each 
other, or even contradictory; however, evolutionary theories of aging 
have suggested that some traits that have been selected to optimize 
health during the period of reproductive fitness can have unselected 
and deleterious effects later in life. Thus, replicative senescence may 
have been selected, at least in mammals, to help ensure the relative 
freedom from cancer that indeed characterizes early and middle 
adulthood. This same process, however, may have deleterious effects 
later in life because nondividing, dysfunctional senescent cells accumu­
late. The accumulation of dysfunctional senescent cells may lead not 
only to the decline in tissue function and integrity that is a hallmark 
of aging, but also to the rise in cancer that occurs with age (Campisi, 
1997b). Understanding the causes and effects of cell senescence may 
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be extremely important for knowing whether and how we can prev.ent 
the loss of functional and proliferative homeostasis associated with aging. 
The senescence counting mechanism The number of divisions 
that normal cells undergo before senescence depends on the species, 
age, and genetic background of the donor and the cell type (reviewed 
in Stanulis-Praeger, 1987; Goldstein, 1990; Campisi et aI, 1996). This 
number can be large: 6(}-80 doublings for fetal or neonatal human 
cells. There is now substantial evidence that cells sense the number of 
completed divisions, at least in part, by the length of their telomeres 
(Shay and Wright, 1991; Levy et aI, 1992; Allsop and Harley, 1995; 
Harley and Villeponteau, 1995; Bodnar et aI, 1998). 
Telomeres are the ends of linear chromosomes, consisting of the 
repetitive sequence TTAGGG in vertebrates, and specialized proteins. 
The telomeric sequence and its binding proteins form a distinctive 
structure (Blackburn, 1991; Tommerup et ai, 1994) that prevents 
chromosome fusions, translocations, and nondysjunctions. Thus, telom­
eres are essential for maintaining the stability of eukaryotic genomes. 
Because DNA polymerases are unidirectional and require a labile 
primer, each round of replication leaves some 3' bases at the telomere 
unreplicated (Levy et aI, 1992). Telomerase, a multimeric enzyme that 
adds telomeric repeats to chromosome ends de novo (Blackburn, 1992), 
is not expressed by most normal somatic cells. Thus, for most cells, 
the telomeres shorten with each cell cycle, and it has been proposed 
that one or more critically short telomere triggers replicative senescence 
(Harley et ai, 1990; Hastie et aI, 1990; Allsop et ai, 1992, 1995). 
Two, possibly three, cell types do not appear to undergo replicative 
senescence. These are the cells that comprise the germ line, very early 
embryonic cells, and many tumor cells. These replicatively immortal 
cells, in contrast to most normal somatic cells, also express telomerase 
activity (Kim et aI, 1994; Wright et aI, 1996; reviewed in Harley and 
Villeponteau, 1995; Campisi, 1997a). 
Although telomerase is frequendy associated with replicative immor­
tality, it is neither sufficient nor necessary for unlimited cell division 
(reviewed in Harley and Villeponteau, 1995; Campisi, 1997a). For 
example, normal human T cells express telomerase in response to 
mitogenic stimulation, but the telomeres of these cells none the less 
shorten and the cells inevitably senesce (Vaziri et ai, 1993; Buchkovich 
and Greider, 1996; Effios, 1996; Weng et ai, 1996). Telomerase is also 
expressed by human basal epidermal keratinocytes, or at least by 
putative epidermal stem cells present in the keratinocyte cultures, but 
all cells in these cultures none the less senesce (Harlebachor and 
Boukamp, 1996). Thus, telomerase activity per se is insufficient to 
prevent telomere shortening and cell senescence. The level of telomerase 
expressed by human T cells and keratinocytes may be inadequate to 
completely prevent telomere shortening. Altematively, telomerase may 
have only limited access to the telomeres in these cells. In addition, 
there are now several examples of immortal human tumor cells that 
do not express any detectable telomerase (Bryan et aI, 1995; Bryan and 
Reddel, 1997). Thus, telomerase is neither necessary nor sufficient for 
maintaining telomere length. 
Very litde is known - in mammalian cells - about why shortened 
telomeres should infiuence cell proliferation or other aspects of the 
senescent cell phenotype (discussed below) so strongly. Evidence from 
yeast, however, suggests three possibilities (reviewed in Campisi, 
1997a): (i) a short telomere could trigger an irreversible DNA damage 
response; (ii) shortened telomeres could reduce the extent of telomeric 
heterochromatinization, which can induce the expression of previously 
silenced genes; (iii) shortened telomeres could release transcription 
factors that act at other sites in the genome to activate or repress gene 
expression. 
Genetics of replicative senescence The finite replicative life-span 
of cells is a dominant phenotype. This conclusion is based primarily 
on somatic cell fusion studies in which proliferating normal human 
cells ,'Jere fused to immortal tumor-derived human cells. In the majority 
of c.,:"',, the hybrid cells proliferated for some tinle, but eventually 
sene, .d (Pereira-Smith and Smith, 1983). Moreover, fusions between 
different immortal human tumor cell lines often - but not always, as 
discussed below - produced hybrid cells that senesced (Pereira-Smith 
and Smith, 1988). These studies strongly suggest that replicative 
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Figure 3. Cell cycle regulatory genes whose expression or activity is altered in senescent cells. Senescent human fibroblasts fail to express three transcription 
factors whose activity is essential for cells to initiate the S phase of the cell cyele. These are the c-fos proto-oncogene, the Idl and 1d2 inhibitors of bHLH 
transcription factors, and the E2F transcription factor. The lack of E2F activity may be an immediate cause for the failure of senescent cells to initiate DNA 
synthesis. Lack of E2F activity is very likely a direct cause for the failure of senescent cells to express many of the genes needed for DNA replication, ineluding 
cyclin A and cdc2 kinase, as well as thymidylate synthetase (ts), thymidine kinase (tk), dihydrofolate reductase (dhfr), and DNA polymerase alpha (DNApol). Lack 
of E2F activity, in tum, is most likely due to the high levels of the p21, and possibly p16, inhibitors of cyelin-dependent kinases (cdks). Inhibition of cyclin­
dependent kinases prevents the phosphorylation of the retinoblastoma tumor suppressor protein (Rb), which is required for the release and activation of E2F. 
senescence is a genetically dominant trait, and that replicative immortal­
ity is genetically recessive. 
The ability of some, but not all, fusion pairs of immortal human 
cells to produce hybrids that are not immortal has led to the identification 
of four complementation groups for replicative immortality (Pereira­
Smith and Smith, 1988). At present, three of these complementation 
groups have been assigned to specific human chromosomes. Thus, 
normal human chromosomes 4, 1, and 7 have been shown to reverse 
the immortality (i.e., induce senescence) of multiple cell lines assigned 
to the complementation groups B, C, and D, respectively (reviewed 
in Campisi et ai, 1996). The senescence-inducing genes that reside on 
these chromosomes have not yet been cloned. Taken together, the 
results of these cell and chromosome fusion studies suggest that at least 
four rustinct, dominant-acting genetic loci act to limit the replicative 
potential of normal human cells. 
Growth arrest of senescent cells As noted earlier, senescent cells 
arrest growth with a G1 DNA content and cannot be stimulated to 
proliferate by any known combination of physiologic mitogens. Because 
this growth arrest is a dominant trait, it has long been proposed that 
senescent cells express one or more inhibitors of cell cycle progression 
that can act in a trans-dominant fashion. 
The growth arrest associated with cellular senescence has been 
sturued most extensively in cultured human fibroblasts (Stanulis­
Praeger, 1987; Goldstein, 1990; Campisi et ai, 1996). From these 
sturues, it appears that many genes, including at least three proto­
oncogenes, remain mitogen-inducible in senescent cells. Thus, senes­
cent cells do not fail to proliferate due to a general breakdown of 
growth factor signal transducing mechanisms. 
Replicative senescence causes the selective repression of a few 
positive-acting, growth regulatory genes whose expression is important 
for G 1 progression and DNA synthesis. In fibroblasts, these genes 
include the c-fos proto-oncogene (Seshadri and Campisi, 1990), the 
helix-loop-helix Id-l and Id-2 genes (Hara et ai, 1994), and the E2F-
1 (Diroti et ai, 1994) and E2F-5 (Good et ai, 1996) components of 
the E2F transcription factor. In adrution, the retinoblastoma tumor 
suppressor protein (pRb) remains in its growth suppressive form (i.e., 
remains constitutively underphosphorylated) (Stein et ai, 1990). Thus, 
the immediate cause for the growth arrest of senescent cells appears to 
be a deficiency in a few, key positive-acting growth regulators (Fig 3). 
In adrution to deficiencies in positive growth regulators, senescent 
human fibroblasts overexpress two negative growth regulators: the p21 
and p16 inhibitors of eyclin-dependent protein kinases (Noda et ai, 
1994; Hara et ai, 1996a). These high levels of p21 and p16 are very 
likely responsible for the accumulation of inactive cyclin-dependent 
protein kinase complexes (Dulic et ai, 1993), and thus the constitutive 
underphosphorylation of pRb (Stein et ai, 1990), in senescent cells. 
Furthermore, because p21 can inhibit E2F by both pRb-dependent 
and pRb-independent mechanisms (Dimri et ai, 1996), the high level 
of p21 may well be responsible for the lack ofE2F activity in senescent 
cells (Dirori et ai, 1994; Good et ai, 1996) (Fig 3). 
p16 and p21 are obvious candidates for dominant inhibitors of cell 
proliferation expressed by senescent cells. The mechanisms responsible 
for the senescence-associated increase in these growth inhibitors are 
not known. It is unlikely, however, that p16 and p21 are the only 
growth inhibitors expressed by senescent cells. For example, indirect 
evidence suggests that senescent cells express at least one adrutional 
growth inhibitor that may belong to a family of basic helix-loop-helix 
transcription factors (Hara et aI, 1996a). Moreover, the upstream 
regulators of p16 and p21 expression in senescent cells, which have 
yet to be identified, may induce additional growth inhibitory genes in 
the cells. 
Functional changes in senescent cells The arrest of cell prolifera­
tion is clearly the most important feature of replicative senescence with 
regard to its role in tumor suppression; however, in adrution to an 
irreversible growth arrest, senescent cells rusplay two other pheno­
typic changes. 
First, senescence cells acquire resistance to programmed cell death 
or apoptosis. The mechanism by which senescent cells resist death in 
response to apoptotic stimuli is not well understood, but may involve 
a stabilization of the cell death-protecting protein, bcl-2 (Wang, 1995). 
The fact that senescent cells are resistant to apoptosis underscores the 
rustinction, often blurred in the literature, between cell death and cell 
senescence. This fact may also explain why senescent cells accumulate 
with age in the skin, and possibly other tissues (Dimri et ai, 1995). 
Second, senescent cells show sometimes striking changes in rufferenti­
ated functions. The functions that are altered by senescence depend 
on the cell type. For example, senescent human fibroblasts and 
endothelial cells overexpress the inflammatory cytokine interleukin-1a 
(Maier et ai, 1990), and senescent human endothelial cells overexpress 
the cell-specific adhesion molecule ICAM (Maier et ai, 1993). On the 
other hand, senescent mammary epithelial cells overexpress the beta 
isoform of the retinoic acid receptor (Swisshelm et aI, 1994). Very little 
is known about the mechanisms that alter rufferentiated gene expression 
in senescent cells; however, as is the case with the growth and 
differentiation of many mammalian cells, the changes in differentiation 
appear to be tightly linked to the arrest of cell proliferation. 
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Table I. Secreted molecules expressed/overexpressed by 
senescent cells 
Molecule 
Interstitial collagenase 
Elastase 
Stromelysin 
Thrombospondin 
Heregulin 
Erb-B receptor ligand 
Epidermal growth factor-like repeat protein 
Plasminogen activator inhibitor 
Interleukin 1 
Action 
Disrupts stroma 
Disrupts stroma 
Disrupts stroma 
Anti-angiogenic 
Growth stimulation 
Growth stimulation 
Pro-thtomobotic 
Pro-inflammatory 
The changes in cell function that are associated with replicative 
senescence can have rather profound consequences for cell - and, at 
least in principle, tissue - function. This is particularly true in the skin. 
For example, presenescent dermal fibroblasts express low levels of 
collagenase and stromelysin, which are matrix metalloproteases that 
degrade extracellular matrix proteins. They also express relatively high 
levels of the matrix metalloproteinase inhibitors TIMP-1 and TlMP-
3 (tissue inhibitor of metalloproteinases 1 and 3). Upon senescence, 
matrix metalloproteinase expression rises and tissue inhibitor of metallo­
proteinases expression falls (West et ai, 1989; Millis et aI, 1992; Wick 
et aI, 1994). Thus, in dermal flbroblasts, replicative senescence entails 
a fairly dramatic switch in phenotype - from a matrix-producing to a 
matrix-degrading phenotype. One of the hallmarks of aging skin is a 
reduction and disorganization of dermal collagen. The phenotypic 
switch to matrix degradation shown by senescent dermal fibroblasts, 
together with the evidence that senescent fibroblasts accumulate with 
age in the dermis (Dimri et aI, 1995), suggest that replicative senescence 
may contribute to the dermal atrophy that occurs with age. 
DISCUSSION 
There are several examples of senescent cells elaborating cytokines, 
extracellular matrix-modifYing enzymes, and other molecules that 
can act at a distance, and thus have far-ranging effects on the 
microenvironment of neighboring cells (Table I; reviewed in Campisi 
et aI, 1996). These molecules are very likely to disrupt tissue integrity 
and function, a hallmark of aging. Given that senescent fibroblasts and 
keratinocytes accumulate with age in human skin, it is conceivable 
that the decline in the integrity and function of the skin, and possibly 
other tissues, associated with aging is due to the presence of senescence 
cells (Fig 4). 
In addition to the increase in interleukin-1 and matrix metallo­
proteinases and the decrease in tissue inhibitor of metalloproteinases, 
our preliminary data suggest that senescent fibroblasts overexpress 
heregulin, an EGF-like cytokine that modulates the growth and 
differentiation of breast and other epithelial cells (Acosta, Lupu, and 
Campisi, unpublished data. Heregulin is also a potent stimulator of 
growth for breast epithelial cells that have an amplification of the 
erbB-2 receptor gene (Lupu et aI, 1996). Thus, senescent stromal cells 
may alter the balance of growth and differentiation of normal epithe­
lium; they may also promote the neoplastic growth of epithelial cells 
that have acquired potentially oncogenic mutations but have been 
held in check by their (presenescent) microenvironment (Campisi, 
1997b) (Fig 5). 
Thus, it is possible that replicative senescence, which may well have 
evolved to keep us relatively cancer free during the fust half of human 
life-span, may have the unselected deleterious effects later in life of 
contributing to the loss of integrity and function of mitotic tissues and 
promoting the growth of preneoplastic cells. 
The strong evidence that replicative senescence is a tumor suppressive 
mechanism argues against the wisdom of attempting to completely 
prevent or reverse replicative senescence. Rather, much of our efforts 
should be focused on understanding the basis for the functional 
changes that occur in senescent cells, and suppressing their appearance. 
Alternatively, it may be possible to selectively kill senescent cells. In 
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Figure 4. The accumulation of senescent cells may promote the loss of 
skin integrity and function with age. Because senescent cells accumulate 
with age in human skin, and secrete degradative enzymes and inflantmatory 
cytokines, skin aging may be at least partially due to the replicative senescence 
of stromal and epithelial cells. 
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Figure 5. The accumulation of senescent cells may promote the growth 
of mutated preneoplastic cells. Because senescent cells accumulate with age, 
and secrete enzymes that disrupt the cellular microenvironment and growth 
factors that can stimulate tumor cell growth, the exponential rise in cancer with 
age may be in part due to the presence of senescent cells in the vicinity of 
initiated preneoplastic cells. 
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either case, the goal may be to reduce or eliminate the deleterious effects 
of senescent cells, without increasing the risk of developing cancer. 
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